Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 23;20(1):75.
doi: 10.1186/s13024-025-00845-w.

Mechanisms of interventions targeting modifiable factors for dementia risk reduction

Affiliations
Review

Mechanisms of interventions targeting modifiable factors for dementia risk reduction

Anna Matton et al. Mol Neurodegener. .

Abstract

The global prevalence of dementia is increasing. With no widely available and accessible treatments to halt or reverse the progression of dementia, exploring preventative strategies is critical. Lifestyle-based interventions show promise in preventing or delaying dementia onset. However, understanding the complex and multifactorial mechanisms underlying dementia, and how interventions target these pathways, is essential for developing personalized and effective strategies. In this review, we examined the current evidence of the mediating pathways in dementia risk reduction. We focused on mechanisms investigated in single-domain interventions on physical exercise, cognitive training, diet, metabolic/cardiovascular or psycho-social risk factors in line with those combined in the landmark FINGER trial. Additionally, we synthesized existing literature on mechanisms of action in multimodal interventions combining multiple lifestyle changes. Most evidence was identified in relation to neuroimaging biomarkers with positive effects for all intervention components. The evidence among fluid biomarkers of Alzheimer's disease and related disorders (ADRD) (amyloid-beta peptide (Aβ), tau and neurofilament light chain (Nfl)) vascular markers, inflammatory markers, and neurotrophins were less conclusive, though physical exercise consistently appeared to impact several of these pathways. The findings of this review underscore the potential of lifestyle-based interventions in modulating several different types of pathophysiological pathways associated with dementia. As the number of dementia cases reach epidemic proportions, a multifaceted approach is needed. We propose that the next critical step in dementia prevention/risk reduction is to refine existing intervention tools and develop an adaptive platform that integrates different lifestyle interventions tailored to individual risk profiles and needs. Understanding the underlying mechanisms and biomarkers related to modifiable risk factors will be instrumental to optimising these interventions.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: M.Bal. is employed at the Swedish Medical Products Agency, SE-751 03 Uppsala, Sweden. The views expressed in this paper do not necessarily represent the views of this Government agency.

Figures

Fig. 1
Fig. 1
Schematic overview of risk reduction strategies, and the main dementia-related mechanisms and mediators that have been investigated in the context of lifestyle intervention RCTs and included in this review. Abbreviations: BDNF: brain-derived neurotrophic factor; Aβ: amyloid beta peptide; p-tau: phosphorylated tau protein
Fig. 2
Fig. 2
Summary of results. Type of biomarkers are listed in the left panel (Imaging, ADRD fluid biomarkers and Other fluid biomarkers). Columns represents the intervention domains included in this review (Physical exercise, Cognitive training, Dietary intervention, CVD/metabolic risk reduction, Sleep/Mindfulness with Psycho-social health and Multimodal intervention). The number of studies are indicated by dot size and colour represents positive (green), neutral (grey) or negative (red) results from the trials

References

    1. Wolters FJ, Chibnik LB, Waziry R, Anderson R, Berr C, Beiser A, et al. Twenty-seven-year time trends in dementia incidence in Europe and the United States. Neurol. 2020;95(5): e519. - PMC - PubMed
    1. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105–25. - PMC - PubMed
    1. Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2016;2016(4):459–509. - PubMed
    1. World Health Organization (WHO) Fact Sheet on Dementia. Web-page. 2023. https://www.who.int/news-room/fact-sheets/detail/dementia.
    1. Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of Aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis. 2022;9:197. - PubMed